Navigation Links
NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
Date:9/5/2007

Pharmaceutical Industry Veteran Richard Franco and Entrepreneur Anthony

Ciabattoni Join NeoMatrix Board of Directors

IRVINE, Calif., Sept. 5 /PRNewswire/ -- NeoMatrix, developer of the HALO(TM) Breast Pap Test, the first automatic, noninvasive test designed to identify breast cancer risk, announced today that the company has closed a Series C round of equity financing. The financing will enable an expanded market release of the HALO System, which is designed to test asymptomatic women for the presence of atypical ductal hyperplasia (ADH), a known biomarker that can be a precursor to breast cancer. ADH is often found in the breast years earlier than a lesion might be found on a mammogram or a self exam, facilitating early follow-up and treatment or chemoprevention measures.

"We appreciate the continued support of our investors as we've surpassed more than 30 placements in Ob-Gyn and primary care offices around the country," said Paul J. Fitzpatrick, chief executive officer of NeoMatrix. "This fundraising has enabled us to hire our first sales representatives, expand our marketing team and to develop the infrastructure and marketing programs required to drive awareness and adoption of the HALO system. It also allowed us to convert or retire 100% of the debt previously used to finance the research and development of both the HALO system and its broad patent protection.

"In addition to our initial success in placing systems in physician offices, we have also recently established relationships with a number of breast specialists and breast centers who have agreed to help introduce HALO to their local primary-care referral networks. Although gynecologists and other primary care physicians are responsible for breast cancer screening of well, or asymptomatic women, breast specialists, often practicing in multi-specialty breast centers, assume responsibility for follow-up and treatment of high-risk patients," added Fitzpatrick.

'/>"/>
SOURCE NeoMatrix, LLC
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 2015 Global Specimen Solutions, Inc. ... on specimen management and informatics, announced today that ... Solutions, Inc. is excited to catapult our growing ... will further enhance our proprietary informatics tools and ... research. GSS has proved rapid market uptake of ...
(Date:3/6/2015)... March 6, 2015 BioSpecifics Technologies Corp. (NASDAQ: ... in class collagenase-based products marketed as XIAFLEX ® ... XIAPEX ®  in the EU, announced today that it ... at 8:30 a.m. ET on Friday, March 13, 2015 ... financial results and provide a corporate update. ...
(Date:3/6/2015)... 2015   Senomyx , Inc. (NASDAQ: ... technologies to discover, develop, and commercialize novel flavor ingredients ... John Poyhonen , the Company,s President and Chief ... President and Chief Financial Officer, will present an overview ... March 11, at 2:00 p.m. Eastern Time (11:00 a.m. ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Transparency Market Research ... and Other Crops - Global Industry Analysis, Size, Share, Growth, ... the global isoxaflutole market was valued at US$ 116.3 Mn ... by 2020, expanding at a CAGR of 5.1% from 2014 ... isoxaflutole stood at 2,569.5 kilo tons in 2013. , Isoxaflutole ...
Breaking Biology Technology:Global Specimen Solutions, Inc. Closes Series A Funding 2Global Specimen Solutions, Inc. Closes Series A Funding 3BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2014 Financial Results on Friday, March 13, 2015 2SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE THE 27TH ANNUAL ROTH CONFERENCE 2Isoxaflutole Market is Expected to Reach US$ 163.0 Mn by 2020 : Transparency Market Research 2Isoxaflutole Market is Expected to Reach US$ 163.0 Mn by 2020 : Transparency Market Research 3
... DCGN ) today announced its consolidated financial results ... conference call to discuss the,year,s results and operating highlights ... EDT/12 noon GMT (details below)., Net loss for ... to $85.5 million for the full year 2006. Basic ...
... JOSE, Calif., March 12 Oncolys BioPharma,Inc. (Tokyo, ... USA),announced today that they have entered into a ... throughout Asia, Tacere,s,RNA interference (RNAi)-based Hepatitis C virus ... agreement resulted from the,strategic alliance entered into by ...
... WILMINGTON, Del., March 12 AstraZeneca (NYSE:,AZN) announced ... two,pivotal Phase III studies for vandetanib, the company,s ... of,non-small cell lung cancer (NSCLC). The two studies ... cell lung Cancer) and ZEAL (ZACTIMA,Efficacy with Alimta ...
Cached Biology Technology:deCODE Genetics Announces Full-year 2007 Financial Results 2deCODE Genetics Announces Full-year 2007 Financial Results 3deCODE Genetics Announces Full-year 2007 Financial Results 4deCODE Genetics Announces Full-year 2007 Financial Results 5deCODE Genetics Announces Full-year 2007 Financial Results 6deCODE Genetics Announces Full-year 2007 Financial Results 7deCODE Genetics Announces Full-year 2007 Financial Results 8deCODE Genetics Announces Full-year 2007 Financial Results 9Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug 2Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug 3AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC) 2AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC) 3
(Date:3/5/2015)... 5, 2015 In Brazil , ... already using these solutions and 42 percent planning to invest ... approximately 25 percent of the companies will be investing in ... majority of companies in the region are currently opting for ... model will command significant attention in the coming years. This ...
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biometrics Market Forecast and Opportunities, ... The market for biometric authentication systems is projected ... till 2020 The driving forces for ... needs, government projects and constant development in technology. ...
(Date:3/3/2015)... 3, 2015 Cryoport, Inc. (OTCBB: ... cryogenic logistics solutions for the life sciences ... cell lines, clinical research organizations, vaccine manufacturers, ... the expansion of its relationship with ... Hutch") Clinical Research Division with the inclusion ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... East Asia is where the wolf was tamed and became the ... But now researchers at the Royal Institute of Technology (KTH) in ... "For the first time in world history it is possible to ... in time, and how many wolves were tamed," says Peter Savolainen, ...
... and other aquatic fauna in recent centuries are not restricted ... that species in rivers and lakes worldwide also experienced sharp ... is frequently overlooked by natural resource managers, according to an ... , Authors Paul Humphries and Kirk Winemiller argue that as ...
... Three out of ten women who undergo polar body ... of polar body analysis (PBA) is described by researchers in ... edition of Deutsches rtzeblatt International , in which they ... Int 2009; 106(33): 533-8). Polar bodies are by-products of ...
Cached Biology News:Shifting baselines confound river restoration 2New developments in reproductive medicine 2
... antibody raised against a partial recombinant MAK. ... ~ 457 a.a) partial recombinant protein with GST ... Accession: BC039825 ... OMIM: 154235, GeneID: ...
...
Mouse polyclonal antibody raised against a partial recombinant DDEF2. NCBI Entrez Gene ID = 8853...
Mouse monoclonal antibody raised against a full length recombinant SCGB3A2. NCBI Entrez Gene ID = SCGB3A2...
Biology Products: